Home   >  
Cell Cycle/DNA Damage

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials


Chemical Structure Cat. No. Product Name CAS No.
Saroglitazar magnesium Chemical Structure
BCP49279 Saroglitazar magnesium 1639792-20-3
Saroglitazar magnesium is a dual agonist at the PPARα and PPARγ of the peroxisome proliferator-activated receptor (PPAR).
Bocidelpar hemisulfate Chemical Structure
BCP49259 Bocidelpar hemisulfate BH
Bocidelpar, also known as ASP0367 or MA-0211, is a peroxisome proliferator-activated receptor (PPAR) delta agonist.
Bocidelpar sulfate Chemical Structure
BCP49258 Bocidelpar sulfate 2095128-21-3
Bocidelpar is a peroxisome proliferator-activated receptor (PPAR) delta agonist.
Mavodelpar sodium Chemical Structure
BCP49236 Mavodelpar sodium 1604815-32-8
Mavodelpar is a selective PPARδ agonist.
Edaglitazone Chemical Structure
BCP26908 Edaglitazone 213411-83-7
Edaglitazone is a PPARγ agonist potentially for the treatment of type 2 diabetes. Edarglitazone, restores acute inflammatory responses to cerebral hypoxia-ischemia in the diabetic ob/ob mouse.
PTGR2-IN-1 Chemical Structure
BCP48929 PTGR2-IN-1 349093-44-3
PTGR2-IN-1 is a potent PTGR2 inhibitor with an IC50 of ~0.7 μM.
Elafibranor Chemical Structure
BCP31152 Elafibranor 824932-88-9
Elafibranor (GFT505) is an agonist of the peroxisome proliferator-activated receptor-α(PPAR-alpha) and peroxisome proliferator-activated receptor-δ(PPAR-δ). It improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation.
Bocidelpar Chemical Structure
BCP45760 Bocidelpar 2095128-20-2
Bocidelpar is a peroxisome proliferator-activated receptor (PPAR) delta agonist.
SR1664 Chemical Structure
BCP45759 SR1664 1338259-05-4
SR1664 is a potent and selective PPARγ inhibitor with potential antidiabetic activity.
AMG-131 Chemical Structure
BCP45654 AMG-131 315224-26-1
AMG-131 is a hypoglycemic agent. It is a potent PPARγ partial agonist that displays robust glucose-lowering activity in rodent models of diabetes while exhibiting a reduced side-effects profile compared to marketed TZDs.
123下一页末页共 61 条记录 1 / 7 页